



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/858,332	05/15/2001	Grigoriy S. Tchaga	CLON-056CIP	2176

24353 7590 03/31/2003

BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK, CA 94025

EXAMINER

KERR, KATHLEEN M

ART UNIT	PAPER NUMBER
----------	--------------

1652

20

DATE MAILED: 03/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

20

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The reply filed on February 4, 2003 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): full sequence compliance (see below 1-4). See 37 C.F.R. ' 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 C.F.R. ' 1.136(a).

(1) The description of Figure 3 (paragraph 0011) is inadequate to satisfy the sequence rules because it is unclear which SEQ ID NOs identify which sequences in the figure. The Examiner suggests amending the figure to render this clear. Appropriate amendments to the drawings are by way of filing substitute sheets with changes sketched in red ink and filing instructions to replace the originally filed drawings with the amended sheets (see M.P.E.P. ' 608.02(p)).

(2) SEQ ID NO: 21, as found in paragraph 0060 and Claim 1, does not adequately represent the sequence described in the specification. In the sequence listing, X1-X6 are listed simply as "X" while in the specification each of X1, X2, etc. have particular limitations that must be entered into the sequence listing. Amendment to the sequence listing is required to add these limitations and to distinguish the X's.

(3) SEQ ID NO: 23, as found in paragraph 0063 and Claim 1, does not adequately represent the sequence described in the specification. In the sequence listing, X1 and X2 are listed simply as "X" while in the specification each of X1 and X2, must be an amino acid with an acidic side chain (Asp, Glu, His). Amendment to the sequence listing is required to add these limitations and to distinguish the X's.

(4) Also, in paragraph 0063, four specific peptides, which are particular embodiments of SEQ ID NO:23, are described and must be specifically identified by individual SEQ ID NOs.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kathleen M Kerr whose telephone number is (703) 305-1229. The examiner can normally be reached on Monday through Friday, from 8:30am to 5pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathupura Achutamurthy can be reached on (703) 308-3804. The fax phone number for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

KMK

March 27, 2003

Kathleen M Kerr